• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » FDA clears Cellex antibody test for COVID-19, not Bodysphere’s

FDA clears Cellex antibody test for COVID-19, not Bodysphere’s

April 2, 2020 By Sean Whooley

The FDA yesterday informed Cellex  that it is issuing emergency use authorization (EUA) for the company’s SARS-CoV-2 antibody test for detecting coronavirus.

Cellex (Research Triangle Park, N.C.) is touting its rapid test as the first of its kind to receive authorization amid the coronavirus crisis. It is a lateral flow immunoassay designed for the qualitative detection and differentiation of IgM and IgG antibodies to SARS-CoV-2 (the virus causing COVID-19) in serum, plasma or venipuncture whole blood specimens.

The FDA letter specified that emergency use of the test is limited to authorized laboratories. Results from the test should not be used as the sole basis for diagnosis, according to the agency.

Those results are solely for the detection of the antibodies that are generated as part of the human immune response to the virus. IgM antibodies are detectable in blood several days after the initial infection, while IgG antibodies become detectable later in the process after infection. Positive results for both antibodies could occur after infection and can be indicative of acute or recent infection.

Meanwhile, Bodysphere, which reported that its SARS-CoV-2 rapid test kit was the first to receive an FDA nod earlier this week, issued a clarification statement after it turned out the test has not yet been authorized.

“In the rush to get the desperately needed test kits to the front lines, Bodysphere believed when the manufacturer’s product was listed on the FDA registry website, that was the [FDA] notification the emergency use authorization (EUA) was issued,” wrote Bodysphere CEO Charlton Lui. “This misunderstanding does not in any way invalidate the test kits authenticity or effectiveness. Under the FDA policy, upon the manufacturer receiving its acknowledgment letter from the FDA, Bodysphere being named the distributor on the EUA submission, was authorized to market and distribute test kits to any licensed healthcare practitioner in the United States for diagnostic use while the manufacturer awaits word of a final decision on its FDA EUA application. The manufacturer has performed clinical trials and the information from those trials will be made available to any healthcare provider or government official seeking to validate the effectiveness and authenticity of these tests.”

Bodysphere added at the end of the statement that it is “anxiously waiting” issuance of EUA from the FDA for its two-minute coronavirus antibody test. The Los Angeles-based company said its testing kit showcased a 91% clinical specificity rate and a 99% clinical sensitivity rate.

Filed Under: Diagnostics, Featured, Food & Drug Administration (FDA), Genomics/Molecular Diagnostics, Regulatory/Compliance Tagged With: Bodysphere, Cellex, coronavirus, COVID-19, FDA

More recent news

  • Breaking: Sequel to launch twiist automated insulin delivery system next month
  • Dexcom shares U.S. report on CGM benefits for type 2 diabetes
  • Data backs Medtronic MiniMed 780G for type 2, children as company seeks expanded indications
  • Endogenex data supports type 2 diabetes procedure
  • Ambu wins FDA clearance for first single-use cysto-nephroscope

About Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at [email protected].

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy